For best results, Johnson et al. advise combining treatments. For example, the MOSAIC study showed that ivermectin plus brimonidine achieved superior effcacy versus vehicle.3 Additionally, an analysis of four randomized topical treatment trials showed that patients with complete clearing had five more relapse-free months than those who did not clear completely. Based on quality-of-life scores, this study showed that earlier effective treatment and longer remission times also may delay disease progression.4
Researchers continue to discover more about rosacea. Many years ago, she notes, researchers began discussing the association between Helicobacter pylori infection and rosacea symptoms.
“Now we are learning more about other gut issues and rosacea symptoms.”
Dr. Johnson is or has been a consultant, speaker and investigator for Galderma.
1. Johnson SM, Berg A, Barr C. Recognizing rosacea: tips on differential diagnosis. J Drugs Dermatol. 2019;18:888-894.
2. Alexis AF. Rosacea in patients with skin of color: uncommon but not rare. Cutis. 2010;86:60-62.
3. Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909-916.
4. Webster G, Schaller M, Tan J, et al. Defining treatment success in rosacea as “clear” may provide multiple patient benefits: results of a pooled analysis. J Der- matol Treat. 2017;28:469-474.